Predictors of Response to Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancer and Pathological Evaluation of HER2 Heterogeneity
Modern Pathology · 2026-03 · 39 (3) · 100935
DOI: 10.1016/j.modpat.2025.100935 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2026-03. Verfasst von Jintao Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University …. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Neoadjuvant Therapy, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Wu Jieping Medical Foundation.
Abstract (Originalsprache)
Human epidermal growth factor receptor 2 (HER2) gene amplification and heterogeneity influence anti-HER2 therapy efficacy, but quantitative assessment of HER2 expression heterogeneity remains scarce. This study evaluates HER2 protein heterogeneity and its effect on neoadjuvant therapy (NAT) outcomes in HER2-positive breast cancer. In total, 295 patients with HER2-positive breast cancer treated with neoadjuvant anti-HER2 therapy were included. HER2 expression was quantified by the percentage of HER2-stained cells across intensities, and heterogeneity was assessed using quadratic entropy. The overall pathological complete response (pCR) rate was 51.86%. Patients with HER2 heterogeneity showed a 24.5% pCR rate, significantly
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong; Department of Pathology, Shenzhen People's Ho…
- Department of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong; Precision Breast PATHology Lab, Li Ka Shing I…
- Department of Pathology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.
- Department of Surgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.
Förderung
- Wu Jieping Medical Foundation
Zitieren
APA
Hu, J., Tsang, J. Y., Liu, J., Hu, H., Guo, D., & Tse, G. M. (2026). Predictors of Response to Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancer and Pathological Evaluation of HER2 Heterogeneity. Modern Pathology, 39(3), 100935. https://doi.org/10.1016/j.modpat.2025.100935
Vancouver
Hu J, Tsang JY, Liu J, Hu H, Guo D, Tse GM. Predictors of Response to Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancer and Pathological Evaluation of HER2 Heterogeneity. Modern Pathology. 2026;39(3):100935. doi:10.1016/j.modpat.2025.100935
BibTeX
@article{Hu2026,
author = {Hu, Jintao and Tsang, Julia Y and Liu, Jianlan and Hu, Hong and Guo, Dajiang and Tse, Gary M},
title = {Predictors of Response to Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancer and Pathological Evaluation of HER2 Heterogeneity},
journal = {Modern Pathology},
year = {2026},
volume = {39},
number = {3},
pages = {100935},
doi = {10.1016/j.modpat.2025.100935}
}
EUVIMED